Clinical Trial Update: A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating the combination of Ceralasertib and Durvalumab in adults with advanced or metastatic non-small c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ceralasertib (ceralasertib)
• Durvalumab (durvalumab)

Snippet

Sponsor: AstraZeneca | Conditions: Advanced or Metastatic NSCLC | Phase 2 | Status: ACTIVE_NOT_RECRUITING